1. 1) Mathieu C, Gillard P, Benhalima K. Insulin analogues in type 1 diabetes mellitus: getting better all the time. Nat. Rev. Endocrinol., 13, 385–399 (2017).
2. 2) Maiorino MI, Petrizzo M, Capuano A, Giugliano D, Esposito K. The development of new basal insulins: is there any clinical advantage with their use in type 2 diabetes? Expert Opin. Biol. Ther., 14, 799–808 (2014).
3. 3) Garber AJ. Will the next generation of basal insulins offer clinical advantages? Diabetes Obes. Metab., 16, 483–491 (2014).
4. 4) Moroz E, Matoori S, Leroux JC. Oral delivery of macromolecular drugs: where we are after almost 100 years of attempts. Adv. Drug Deliv. Rev., 101, 108–121 (2016).
5. 5) Ismail R, Csoka I. Novel strategies in the oral delivery of antidiabetic peptide drugs—Insulin, GLP 1 and its analogs. Eur. J. Pharm. Biopharm., 115, 257–267 (2017).